Biohaven Q4 2022 Earnings Report
Key Takeaways
Biohaven Ltd. reported a net loss of $201.1 million for the three months ended December 31, 2022. As of December 31, 2022, the company had cash and equivalents of $465.3 million and no debt. The company is focused on advancing its pipeline of therapies for neurological and neuropsychiatric diseases.
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights.
Completed Phase 1 SAD/MAD study with BHV-7000 from Kv7 ion channel activator platform and reported preliminary safety and tolerability data.
Commenced enrollment in pivotal Phase 3 study with myostatin targeting agent, adnectin taldefgrobep alfa, for spinal muscular atrophy.
Presented preclinical data from IgG degrader, BHV-1300, showing robust reduction of IgG levels.
Biohaven
Biohaven
Forward Guidance
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders and expects to reach significant pipeline milestones in the coming periods.
Positive Outlook
- Initiate EEG study with BHV-7000 in the first half of 2023
- Submit IND with BHV-7010 in epilepsy and mood disorders in the second half of 2023
- Submit IND with BHV-2100 in chronic pain in 2023
- Commence Phase 1 studies with BHV-8000 in 2023
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023